Amgen (NASDAQ:AMGN – Get Free Report) had its price target increased by research analysts at Canaccord Genuity Group from $366.00 to $384.00 in a note issued to investors on Wednesday. Canaccord Genuity Group’s price target would indicate a potential downside of 1.70% from the company’s current price. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $361.30. Get Amgen alerts:Read Our Latest Research Report on AmgenAmgen Price PerformanceShares of AMGN opened at $390.63 on Wednesday. Amgen Company Profile(Get Free Report)Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California.